To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive
a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles.
Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive
evaluation and ratings from patients.
PhD, Biostatistics, University of Pennsylvania, Philadelphia, PA, 2012
BSE, Systems Engineering, University of Pennsylvania, Philadelphia, PA, 2005
International Biometrics Society
American Statistical Association
Society for Medical Decision Making
Honors & Awards
Student Travel Award, International Conference in Health Policy Statistics, 2011
Jonathan Raz Award, 2010
GlaxoSmithKline Scholar Award, 2010
Statistical methods for observational data
Cost-effectiveness and comparative effectiveness studies
Propensity score methods
Machine learning methods for prediction and variable selection
Assessing sensitivity to unmeasured confounding variables
Tissue microarray analysis
Tumor growth modeling
My research focuses on statistical analysis of observational data, particularly applied to comparative-effectiveness, cost-effectiveness, and population health. Many important healthcare questions are infeasible or impractical to test via randomized controlled trials. Often, the most rigorous way to evaluate hypotheses in the absence of a randomized trial is by extracting and analyzing information from large observational datasets, such as cancer registries, claims files, electronic medical records (EMR), or census data. I develop innovative methods to analyze such data, often using computationally intensive solutions.
Collaborative work with clinicians and scientists
I provide statistical expertise for a wide variety of studies led by Fox Chase Cancer Center investigators, including efficacy analysis of interventions, biomarker analysis and non-therapeutic randomized trials. Often, these studies require advanced statistical analyses or novel applications of existing methods. For example, I developed a novel hierarchical clustering and latent class analysis procedure to evaluate quality of survey responses from an anonymous web panel. (Handorf et al, 2018)
Development of sensitivity analysis methods for cost and cost-effectiveness data
One major drawback of non-randomized data is that groups of patients with different exposures of interest are often systematically different. Although most secondary data allows us to adjust for basic risk factors, such as gender, age and disease characteristics, it is unlikely that all important variables will be available in an observational dataset. These omitted variables, also called unmeasured confounders, may bias conclusions of study results. I developed a comprehensive framework for evaluating the effect of unmeasured confounders of cost and cost-effectiveness outcomes. (Handorf et al, 2013, 2018)
Computationally intensive and machine learning methods
I apply and extend cutting-edge machine learning methods for high-dimensional data.For example, I conducted a comprehensive evaluation of sparse regressions and tree ensemble methods for variable selection when analyzing U.S. Census data.(Handorf 2020) I also use sophisticated ensemble models (e.g. SuperLearner, Bayesian Additive Regression Trees) for estimation of propensity score weights in observational data analysis.
Application of methods for observational data to clinically relevant questions
I have conducted many analyses of large datasets based on questions from clinical collaborators, using methods appropriate for the observational nature of the data and the outcome of interest. For example, I used the National Cancer Database to demonstrate that delays in treatment for head and neck cancers are associated with poorer survival. (Murphy, 2016) I have conducted many studies using data from the SEER registry, linked SEER-Medicare data, and EMR-derived databases.
Vapiwala N., Wong J.K., Handorf E., Paly J., Grewal A., Tendulkar R., Godfrey D., Carpenter D., Mendenhall N.P., Henderson R.H., Stish B.J., Vargas C., Salama J.K., Davis B.J.,Horwitz E.M., A pooled toxicity analysis of moderately hypofractionated proton beam therapy and intensity modulated radiation therapy in early-stage prostate cancer patients. Int J Radiat Oncol Biol Phys. 110(4): 1082-1089, 2021. https://www.ncbi.nlm.nih.gov/pubmed/33539968.
Winer A., Handorf E.,Dotan E., Dosing schedules of gemcitabine and nab-paclitaxel for older adults with metastatic pancreatic cancer. Jnci Cancer Spectrum. 5(5): pkab074, 2021. PMC8438244. https://www.ncbi.nlm.nih.gov/pubmed/34532641.
Wong J.K., Handorf E., Lee D., Jain R., Zhang E., Cooper H.S., Farma J.M., Dotan E.,Meyer J.E., Toxicity and outcomes in older versus younger patients treated with trimodality therapy for locally advanced rectal cancer. J Geriatr Oncol. 11(8): 1331-1334, 2020. PMC7606716. https://www.ncbi.nlm.nih.gov/pubmed/32381438.
Handorf E, Yin Y, Slifker M, Lynch S. Variable selection in social-environmental data: Sparse regression and tree ensemble machine learning approaches. BMC Medical Research Methodology. 2020 Dec 10;20(1):302.
Handorf EA, Heckman CJ, Darlow S, Slifker M, Ritterband L. A hierarchical clustering approach to identify repeated enrollments in web survey data. PLOS One. 2018;13(9):e0204394.
Handorf EA, Bekelman JE, Heitjan DF, Mitra N. Evaluating costs with unmeasured confounding: a sensitivity analysis for the treatment effect. The annals of applied statistics. 2013;7(4):2062-80.
Handorf EA, Heitjan DF, Bekelman JE, Mitra N. Estimating cost-effectiveness from claims and registry data with measured and unmeasured confounders. Statistical methods in medical research. 2018;28(7):2227-42.
Ramamurthy C, Handorf EA, Correa AF, Beck JR, Geynisman DM. Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naive prostate cancer. Urologic oncology. 2019;37(10):688-95.
Gabitova-Cornell L, Surumbayeva A, Peri S, Franco-Barraza J, Restifo D, Weitz N, Ogier C, Goldman AR, Hartman TR, Francescone R, Tan Y, Nicolas E, Shah N, Handorf EA, Cai KQ, O'Reilly AM, Sloma I, Chiaverelli R, Moffitt RA, Khazak V, Fang CY, Golemis EA, Cukierman E, Astsaturov I. Cholesterol Pathway Inhibition Induces TGF-β Signaling to Promote Basal Differentiation in Pancreatic Cancer. Cancer Cell. 2020 Oct 12;38(4):567-583.e11.
Lynch SM, Sorice K, Tagai EK, Handorf EA. Use of empiric methods to inform prostate cancer health disparities: Comparison of neighborhood-wide association study "hits" in black and white men. Cancer. 2020 Jan 1;126(9):1949-1957...Expand
Reese JB, Smith KC, Handorf E, Sorice K, Bober SL, Bantug ET, Schwartz S, Porter LS. A randomized pilot trial of a couple-based intervention addressing sexual concerns for breast cancer survivors. Journal of psychosocial oncology. 2019;37(2):242-63.
Fang CY, Ma GX, Handorf EA, Feng Z, Tan Y, Rhee J, Miller SM, Kim C, Koh HS. Addressing multilevel barriers to cervical cancer screening in Korean American women: A randomized trial of a community-based intervention. Cancer. 2017;123(6):1018-26.
Murphy CT, Galloway TJ, Handorf EA, Egleston BL, Wang LS, Mehra R, Flieder DB, Ridge JA. Survival impact of increasing time to treatment initiation for patients with head and neck cancer in the United States. Journal of clinical oncology. 2016;34(2):169-78.
Gerson JN, Handorf E, Villa D, Gerrie AS, et al. Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era. Journal of clinical oncology. 2019;37(6):471-80.
Churilla TM, Chowdhury IH, Handorf E, Collette L, Collette S, Dong Y, Alexander BM, Kocher M, Soffietti R, Claus EB, Weiss SE. Comparison of local control of brain metastases with stereotactic radiosurgery vs surgical resection: A secondary analysis of a randomized clinical trial. JAMA oncology. 2019;5(2):243-247.
Joshi SS, Handorf EA, Zibelman M, Plimack ER, Uzzo RG, Kutikov A, Smaldone MC, Geynisman DM. Treatment facility volume and survival in patients with metastatic renal cell carcinoma: A registry-based analysis. European urology. 2018;74(3):387-93.
Wang Y, Bernhardy AJ, Nacson J, Krais JJ, Tan YF, Nicolas E, Radke MR, Handorf E, Llop-Guevara A, Balmaña J, Swisher EM, Serra V, Peri S, Johnson N. BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. Nat Commun. 2019 Dec 11;10(1):5661.
Joshi SS, Handorf E, Strauss D, Correa AF, Kutikov A, Chen DYT, Viterbo R, Greenberg RE, Uzzo RG, Smaldone MC, Geynisman DM. Treatment trends and outcomes for patients with lymph node-positive cancer of the penis. JAMA oncology. 2018;4(5):643-9.
Heckman CJ, Darlow SD, Ritterband LM, Handorf EA, Manne SL. Efficacy of an intervention to alter skin cancer risk behaviors in young adults. American journal of preventive medicine. 2016;51(1):1-11.
The following ratings and reviews are based on verified feedback collected from independently administered
patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions.
Patient identities are withheld to ensure confidentiality and privacy.
Learn more about our Patient Experience Ratings.